Company intelligence / Profile preview

Heaton-Brown Life Sciences

Ownership: Private
Development stage: Preclinical

Overview

HBLS was formed to further develop several preclinical oncology programs originally discovered at Novogen Ltd. These include the small molecule Trilexium (TRX-E‑009‑1) and other super-benzopyran compounds, plus an early-stage “ad‑het” series. No clinical results have been reported by HBLS itself as of the latest available information; all programs are/were preclinical at handover

Therapeutic areas: OncologyOther
Modalities: Small molecules ("super-benzopyran" class compounds such as Trilexium/TRX-E series)
Industry: Biotech

Partnerships

Kazia Therapeutics Limited (formerly Novogen Ltd): source/licensor of initial pipeline assets and substantial shareholder/supportive partner

Beyond the preview

Go deeper on Heaton-Brown Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heaton-Brown Life Sciences.

Explore the full profile